JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings. Near-term, if one ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

The company has shown promising results in its preclinical and early clinical trials, particularly with its lead program ...

Neurotech has appointed Dr Anthony Filippis as its managing director to steer the company as it progresses clinical testing ...

Saudi researchers from Qassim University identified Bethlem Myopathy, a rare genetic disorder. The scientific discovery sheds ...

including myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). In DM1, Avidity Biosciences continues to progress with their Phase 3 ...

A Pennsylvania woman, 38, tells PEOPLE that she credits Dateability, a dating app focused on the disabled and chronically ill ...